These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 10882581)
1. Structural prerequisites for intersubtype B and D antigenicity of the third variable envelope region (V3) of human immunodeficiency virus type 1. Lawoko A; Johansson B; Ljunggren J; Fries A; Fredriksson R; Georgievska L; Malmvall B; Pipkorn R; Fenyö EM; Blomberg J J Infect Dis; 2000 Jul; 182(1):49-58. PubMed ID: 10882581 [TBL] [Abstract][Full Text] [Related]
2. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera. Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152 [TBL] [Abstract][Full Text] [Related]
3. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1. Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967 [TBL] [Abstract][Full Text] [Related]
4. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
5. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1. Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies]. Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471 [TBL] [Abstract][Full Text] [Related]
7. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Haynes BF; Ma B; Montefiori DC; Wrin T; Petropoulos CJ; Sutherland LL; Scearce RM; Denton C; Xia SM; Korber BT; Liao HX Virology; 2006 Feb; 345(1):44-55. PubMed ID: 16242749 [TBL] [Abstract][Full Text] [Related]
8. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968 [TBL] [Abstract][Full Text] [Related]
10. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298 [TBL] [Abstract][Full Text] [Related]
11. The antigen/antibody specificity exchanger: a new peptide based tool for re-directing antibodies of other specificities to recognize the V3 domain of HIV-1 gp120. Sällberg M; Sherefa K; Zhang ZX Biochem Biophys Res Commun; 1994 Dec; 205(2):1386-90. PubMed ID: 7802674 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice. Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490 [TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes. Chang SY; Vithayasai V; Vithayasai P; Essex M; Lee TH J Infect Dis; 2000 Aug; 182(2):442-50. PubMed ID: 10915074 [TBL] [Abstract][Full Text] [Related]
15. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. Labrosse B; Treboute C; Brelot A; Alizon M J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952 [TBL] [Abstract][Full Text] [Related]
16. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. Walker PR; Cilliers T; Choge IA; Taylor N; Cohen SS; Morris L J Med Virol; 2006 Oct; 78(10):1262-8. PubMed ID: 16927278 [TBL] [Abstract][Full Text] [Related]
17. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247. Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978 [TBL] [Abstract][Full Text] [Related]
18. Improving on nature: focusing the immune response on the V3 loop. Zolla-Pazner S Hum Antibodies; 2005; 14(3-4):69-72. PubMed ID: 16720976 [TBL] [Abstract][Full Text] [Related]
19. Lack of association between anti-V3 loop antibodies and perinatal transmission of HIV-1 in Kampala, Uganda. Epstein H; Guay L; Hom D; Mmiro F; Ndugwa C; Marum L; Olness K; Piwowar E; Kataaha P; Baenziger J Pediatr AIDS HIV Infect; 1994 Dec; 5(6):350-6. PubMed ID: 11361376 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses. Hewer R; Meyer D Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]